Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study to Evaluate the Safety, Tolerability, and Effect of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), on Markers of HIV Persistence in ART-treated, HIV-infected Adults

Next Previous
Trial Profile

A Phase I Study to Evaluate the Safety, Tolerability, and Effect of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), on Markers of HIV Persistence in ART-treated, HIV-infected Adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VRC 01LS (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics

Most Recent Events

  • 28 Mar 2017 New trial record
  • 16 Feb 2017 Primary endpoint of cell-associated HIV-1 RNA/DNA ratio in total CD4+ cells has not been met, according to results presented at the 24th Conference on Retroviruses and Opportunistic Infections.
  • 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top